Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
about
New Antituberculosis Drugs: From Clinical Trial to Programmatic UseCarbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewManagement of multidrug-resistant TB: novel treatments and their expansion to low resource settingsEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Medical Management of Drug-Resistant TuberculosisBedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanidCost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UKTradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based AnalysisTuberculosis therapy for 2016 and beyond.Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in GermanyGlobal Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient NeedsClofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.Drug-Resistant Tuberculosis: Challenges and Progress.Bedaquiline for the treatment of drug-resistant tuberculosis.Management of drug resistantTB in patients with HIV co-infection.Adverse effects of oral second-line antituberculosis drugs in children.WHO strategies for the programmatic management of drug-resistant tuberculosis.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.News on therapeutic management of MDR-tuberculosis: a literature review.High Rates of Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored Treatment Regimens.Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung DiseaseIn Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.First use of bedaquiline in a patient with XDR-TB in Singapore.First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB.First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challengesExamples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.Operational aspects of bedaquiline implementation in Swaziland: report from the field.Clofazimine for Treatment of Pulmonary Extensively Drug-Resistant Tuberculosis in China.Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.Pulmonary resection for patients with multidrug-resistant tuberculosis based on survival outcomes: a systematic review and meta-analysis.Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.
P2860
Q26741138-6724B630-9D3F-458F-8FFF-5E24327679BEQ26764847-0BAA046C-1D1C-45B7-B7E4-99BC9BDC6A81Q26765394-E09B8F4E-F1AA-46E3-8A13-8279A68BD6D0Q26771997-74519C92-DA1B-4704-8488-27496171FBDCQ26801601-C4C7F847-F586-4D80-A60B-4EA3A015DE03Q26824413-C723E27E-7FE1-4C43-BDB8-68F81EB5EAE0Q27003210-0B45DF10-5D12-458D-B20B-525D2B33A0E2Q28544800-0204F7EE-118D-4BCB-84BD-7B1E3E742517Q28554607-AE5E6173-5630-4919-B00F-2606D73E7210Q30248788-2BDF52CE-97D1-442F-BD68-BF09ADC51235Q30249515-64E543BF-A487-48BC-A69D-ED12132691E5Q33760793-4262B13B-5424-4C88-B081-02B182E85385Q36260334-81D1C899-862A-4AEA-B9E8-990464547677Q36300175-B3943017-4122-4C0B-AC8A-B5185C20276AQ36617085-25C0ED88-EFC3-4384-BB02-97C686DFBA32Q36888058-79D5B1AA-56CD-4BBB-BCD5-10EA9E09776FQ36924283-4FA592D9-D8C6-48C1-963D-E7E7425A8EA2Q38386950-2632A7A5-4399-4AD9-ACD2-A486FD3D249AQ38610637-E289F5A8-F324-45E2-A398-C843EB367764Q38837774-68EC9168-B701-480E-B63A-FC3EF02C3B06Q38856343-8C30FAEC-3245-4A16-B93B-F43570E41749Q38995175-BEC2CA90-248B-4AE9-B6C4-B703D414730FQ39010772-C8ECF495-735F-4446-B61E-7D9043A6E829Q39398924-AE99FE0F-4021-4C3D-A1DE-F1ED2BB4D40EQ39779537-0FBE5CBD-8BAF-43AA-8489-89CC9A3D817FQ40100551-9804DBFE-4BBD-4D58-AD93-EA31F2D259FCQ40419592-810AD86F-6CF6-4278-9E04-1C080EAB64B9Q40441723-88525B4B-7465-4580-BE6D-219872E1912DQ41362907-78F68DE6-7006-43F1-9681-737463041C0BQ42362191-801817C1-8A4B-4C6A-9D82-FF4CF200A605Q42399096-FCB42B0A-5F5F-4568-85B0-791C5D72D2B6Q42399097-1FC6EF3F-ED45-43F2-90BE-5D37B2AEAFA3Q46202128-8BB92D4A-3D1F-4069-B042-2828BC1FEC01Q47121816-83025D3C-6D3D-492D-834A-53680FB6076AQ47645033-E20290A5-22DF-45ED-ABBD-599C30DAA651Q47719751-2E2B4932-80CD-4B9B-8A24-FDC98E670527Q47829817-19E151D1-8E3B-4EE0-9DC1-A133E66EE0BEQ50033600-FA71BFFE-AF93-4A02-AA10-7C333AEAE0BAQ55547799-2FA8B40A-937C-4661-95F7-D64243DC5C8F
P2860
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Compassionate use of bedaquili ...... m analysis of a French cohort.
@en
type
label
Compassionate use of bedaquili ...... m analysis of a French cohort.
@en
prefLabel
Compassionate use of bedaquili ...... m analysis of a French cohort.
@en
P2093
P2860
P50
P356
P1476
Compassionate use of bedaquili ...... m analysis of a French cohort.
@en
P2093
Benoît Henry
Damien Le Dû
Diane Martin
Eric Caumes
MDR-TB Management Group of the ...... ns of the French MDR-TB Cohort
Mathilde Jachym
Nathalie Métivier
P2860
P304
P356
10.1093/CID/CIU786
P407
P577
2014-10-15T00:00:00Z